Nan Ma was born in China. She studied Stomatology at Normal Bethrune University of Medical Sciences, Immunology at the Peking Union Medical College & Chinese Academy of Medical Sciences and made her Ph.D. at the Institute of Bioengineering and Nanotechnology, National University of Singapore. During that period, she investigated the targeted gene therapy by polycation gene vectors on central nervous system. From 2003 to 2011, she was the lab leader of Reference and Translational Center of Stem Cell Cardiac Therapy in Rostock. She, as a junior group leader, was supported for five years by Helmholtz Association on cardiac regeneration. In 2005, she received Hancock Prize of the GST
CS. She was the winner of competition on Research and Innovation Proposals on in MV of 2011.
Her Topic of Materials' Days 2011:
Biomaterials for stem cell enhancement
Stem cells may contribute to tissue regeneration following injury, and this may be only achieved by enhanced stem cell viability and functionality. Here, we developed the polycation-based vectors to deliver the prosurvival gene to bone marrow stem cells (BMSCs). Using an integrated in vitro and in vivo approach, we found that gene preconditioned BMSC could reverse cell apoptosis in vitro and protect cardiac function against acute myocardial injury in vivo. The cardiac protective effect of preconditioned BMSCs associated with an enhanced paracrine effects. We also applied 3 dimensional Laser-Induced-Forward-Transfer (LIFT) cell printing technique and sed seeded with human umbilical vein endothelial cells (HUVEC) and human MSC (hMSC) in a defined pattern for cardiac regeneration on a Polyester urethane urea (PEUU) cardiac patch. Patches were cultivated in vitro or transplanted in vivo to the infarcted zone of rat hearts after LAD-ligation. We demonstrated that LIFT-derived cell seeding pattern definitely modified growth characteristics of co-cultured HUVEC and hMSC leading to increased vessel formation and found significant functional improvement of infarcted hearts following transplantation of a LIFT-tissue engineered cardiac patch. LIFT-based Tissue Engineering of cardiac patches for the treatment of myocardial infarction might improve wound healing and functional preservation.